肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：脊索瘤SOX9表达及其治疗潜力

2017-09-12 MedSci MedSci原创

脊索瘤SOX9治疗
关注

常规的化学治疗方法在治疗脊索瘤时疗效有限。CLIN CANCER RES近期发表了一篇文章，研究SOX9在脊索瘤中发挥的功能及其治疗应用前景。

常规的化学治疗方法在治疗脊索瘤时疗效有限。CLIN CANCER RES近期发表了一篇文章，研究SOX9在脊索瘤中发挥的功能及其治疗应用前景。作者利用免疫组化分析了50例脊索瘤标本SOX9表达。使用western blot和免疫组化分析脊索瘤细胞系中SOX9表达。利用SOX9siRNA抑制SOX9表达。抑制SOX9后表达后通过MTT法检测细胞增殖能力和细胞毒性情况。通过划痕实验及Transwell实验评估SOX9敲除对脊索瘤细胞运动的影响。通过western blot及流式细胞学检测SOX9敲除诱导的细胞凋亡，细胞周期捕获及肿瘤干细胞分子标志表达下调情况。使用MTT法检测SOX9 siRNA联合化疗药阿霉素+顺铂对脊索瘤细胞的影响。组织芯片和免疫组化分析表明SOX9在脊索瘤广泛表达并且高SOX9表达与不良预后有关。RNA干扰敲除SOX9可以抑制脊索瘤细胞生长，降低细胞运动能力并诱导细胞凋亡。此外，SOX9抑制联合化疗药物对脊索瘤细胞有较强的抗肿瘤作用。文章最后认为，SOX9在脊索瘤中起到了关键作用。靶向SOX9为脊索瘤的治疗提供了新的方向。原始出处：Hua Chen,Cassandra

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1945081, encodeId=6a6c19450818c, content=<a href='/topic/show?id=e6c884583d9' target=_blank style='color:#2F92EE;'>#脊索瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84583, encryptionId=e6c884583d9, topicName=脊索瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sun Jun 03 06:33:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243383, encodeId=c466243383ea, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Sep 13 00:12:55 CST 2017, time=2017-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243203, encodeId=22532432039f, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Sep 12 12:36:27 CST 2017, time=2017-09-12, status=1, ipAttribution=)]
    2018-06-03 qindq

    #脊索瘤#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1945081, encodeId=6a6c19450818c, content=<a href='/topic/show?id=e6c884583d9' target=_blank style='color:#2F92EE;'>#脊索瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84583, encryptionId=e6c884583d9, topicName=脊索瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sun Jun 03 06:33:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243383, encodeId=c466243383ea, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Sep 13 00:12:55 CST 2017, time=2017-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243203, encodeId=22532432039f, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Sep 12 12:36:27 CST 2017, time=2017-09-12, status=1, ipAttribution=)]
    2017-09-13 luominglian113

    学习了.谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1945081, encodeId=6a6c19450818c, content=<a href='/topic/show?id=e6c884583d9' target=_blank style='color:#2F92EE;'>#脊索瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84583, encryptionId=e6c884583d9, topicName=脊索瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Sun Jun 03 06:33:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243383, encodeId=c466243383ea, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Sep 13 00:12:55 CST 2017, time=2017-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=243203, encodeId=22532432039f, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Tue Sep 12 12:36:27 CST 2017, time=2017-09-12, status=1, ipAttribution=)]
    2017-09-12 清风拂面

    谢谢分享.学习了

    0